PharmaEssentia

6446.TW

21.81 USD

0.48

+2.25%

Overview

Last close

21.81 usd

Market cap

7.44B usd

52 week high

22.95 usd

52 week low

8.76 usd

Target price

25.9 usd

Valuation

P/E

126.9784

Forward P/E

N/A

Price/Sales

32.9385

Price/Book Value

8.9275

Enterprise Value

6.45B usd

EV/Revenue

25.6045

EV/EBITDA

91.5817

Key financials

Revenue TTM

209.42M usd

Gross Profit TTM

183.16M usd

EBITDA TTM

-6.53M usd

Earnings per Share

0.17 usd

Dividend

N/A usd

Total assets

867.04M usd

Net debt

-583.77M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.